title: Gastric and intestinal phenotypic marker expression in gastric carcinomas and its prognostic significance: immunohistochemical analysis of 136 lesions.
abstract: OBJECTIVE
  It is well known that both gastric and intestinal phenotypic cell markers are expressed in gastric carcinomas, irrespective of their histologic type. However, the clinicopathologic significance of these expressions has not yet been clarified.
  
  
  METHODS
  We analyzed the correlations among gastric and intestinal phenotypic marker expression patterns of the tumor, clinicopathologic findings and the patient's outcome in 136 advanced gastric carcinomas.
  
  
  RESULTS
  Phenotypic marker expression was immunohistochemically evaluated using the monoclonal antibodies 45M1 (anti-human gastric mucin; HGM), CLH5 (anti-MUC6), Ccp58 (anti-MUC2) and 56C6 (anti-CD10). All tumors were classified as gastric (G), gastric and intestinal mixed (GI), intestinal (I) or unclassified (UC) phenotype. Of the 136 gastric carcinomas, 50 (36.8%), 56 (41.2%), 21 (15.4%) and 9 (6.6%) were classified as G, GI, I and UC phenotype, respectively. The G-phenotype tumors were associated with a higher rate of undifferentiated-type and infiltrative histology as compared with the I-phenotype tumors (p < 0.05 and p < 0.001, respectively). Furthermore, both univariate and multivariate analysis of survival revealed the G-phenotype tumor to be associated with a significantly poorer outcome than the I-phenotype tumor (p < 0.05).
  
  
  CONCLUSIONS
  Our present results indicate that the gastric and intestinal phenotypic marker expression pattern of tumors, determined by the combination of HGM, MUC6, MUC2 and CD10 expression, is prognostically useful for patients with gastric carcinoma.
authors.affiliation: Department of Surgery, Toyosu Hospital, Showa University, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Tajima
authors.forename: T
authors.initials: T
authors.lastname: Shimoda
authors.forename: Y
authors.initials: Y
authors.lastname: Nakanishi
authors.forename: N
authors.initials: N
authors.lastname: Yokoyama
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Kawamura
authors.forename: M
authors.initials: M
authors.lastname: Kusano
authors.forename: K
authors.initials: K
authors.lastname: Kumagai
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D015415:Biomarkers; D014408:Biomarkers, Tumor / Q000032:analysis*; D002454:Cell Differentiation; D005260:Female; D005752:Gastric Mucins / Q000032:analysis; D006801:Humans; D007124:Immunoenzyme Techniques; D007421:Intestine, Small / Q000737:chemistry*; D008297:Male; D008679:Metaplasia; D008875:Middle Aged; D055262:Mucin-2; D055272:Mucin-6; D009077:Mucins / Q000032:analysis*; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000032:analysis*; D015260:Neprilysin / Q000032:analysis*; D009928:Organ Specificity; D010641:Phenotype; D011379:Prognosis; D016016:Proportional Hazards Models; D013270:Stomach / Q000737:chemistry*; D013274:Stomach Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D015415:Biomarkers; D014408:Biomarkers, Tumor; D005752:Gastric Mucins; C524625:MUC2 protein, human; C524734:MUC6 protein, human; D055262:Mucin-2; D055272:Mucin-6; D009077:Mucins; D009363:Neoplasm Proteins; D015260:Neprilysin